<DOC>
	<DOCNO>NCT01090427</DOCNO>
	<brief_summary>This study safety efficacy ustekinumab ( CNTO 1275 ) adolescent patient moderate severe psoriasis .</brief_summary>
	<brief_title>A Study Safety Efficacy Ustekinumab Adolescent Patients With Psoriasis ( CADMUS )</brief_title>
	<detailed_description>This randomize ( drug assign chance ) , double-blind ( medical research study neither researcher participant know treatment participant receiving ) , placebo-controlled , parallel ( medical research study compare response two group participant receive different treatment ) , multicenter ustekinumab adolescent participant moderate severe psoriasis . The total duration study 60 week . The study consist 2 part ; Screening period Treatment period . In treatment period participant receive either ustekinumab half standard dosage , ustekinumab standard dosage Placebo . Participants receive ustekinumab half standard dosage ustekinumab standard dosage Week 0 , receive placebo Week 12 participant receive placebo Week 0 randomly assign either ustekinumab half standard dosage ustekinumab standard dosage Weeks 12 , 16 , 28 , 40 . Primarily efficacy evaluate physician 's global assessment ( PGA ) score clear minimal disease . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis without psoriatic arthritis ( PsA ) least 6 month Are candidate phototherapy systemic treatment psoriasis Have screen laboratory test result within study parameter Currently nonplaque form psoriasis Have use therapeutic agent target reduce interleukin12 ( IL12 ) interleukin23 ( IL23 ) , include limited ustekinumab briakinumab Received conventional systemic therapy phototherapy within last 4 week Received biologic therapy within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Ustekinumab</keyword>
	<keyword>Injection</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Stelara</keyword>
	<keyword>Pediatric psoriasis</keyword>
	<keyword>Adolescents</keyword>
</DOC>